Why the study?
Does bevacizumab increase the risk of cardiac ischemia and arterial thromboembolic events in cancer patients?
Does bevacizumab increase the risk of cardiac ischemia and arterial thromboembolic events in cancer patients?
Bevacizumab treatment in cancer patients is associated with a significantly increased risk of cardiac ischemic and arterial thromboembolic events.
Supports ischemic risk monitoring with bevacizumab; confirms elevated cardiac events in aggregated cancer patient data.
Treatment with bevacizumab may significantly increase the risk of cardiac ischemic events in cancer patients.
No takes yet. Share an insight, caveat, or question.
Ranpura et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: